Meeting Banner
Abstract #2030

Ketamine Induced Glutamate Alternations in Treatment-Resistant Depression. A 1H-MRS randomised placebo controlled study.

Rouslan Sitnikov1,2, Mikael Tiger3, and Johan Lundberg3
1Neuroradiology, Karolinska University Hospital, Stockholm, Sweden, 2Clinical Neuroscience, MR Center, Karolinska Institutet, Stockholm, Sweden, 3Centre for Psychiatry Research, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden


Background: The glutamate N-methyl-D-aspartate receptor antagonist ketamine has a rapid antidepressant effect in major depressive disorder (MDD) patients. Though, the ketamine's possible mechanism of action has been debated the main hypothesis was focused around glutamate.

Methods: A proton short-echo MR Spectroscopy was utilised to examined three brain regions Anterior Cingulate Cortex, Hippocampus and Raphe nuclei before and 24-hours after treatment. 28 Selective Serotonin Reuptake Inhibitor resistant MDD patients were randomized to double blind monotherapy with 0.5 mg/kg ketamine or placebo infusion.

Results: glutamate correlates with depression symptoms severity in ACC and HC in opposing ways in ketamine group.

This abstract and the presentation materials are available to members only; a login is required.

Join Here